tiprankstipranks
Trending News
More News >
SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
US Market
Advertisement

SIGA Technologies (SIGA) AI Stock Analysis

Compare
461 Followers

Top Page

SIGA

SIGA Technologies

(NASDAQ:SIGA)

Rating:82Outperform
Price Target:
$8.50
▲(3.03% Upside)
SIGA Technologies scores well due to its strong financial performance, robust earnings call highlights, and attractive valuation. The stock's positive technical indicators further support its potential. However, regulatory challenges in Europe and stagnant revenue growth are risks to consider.

SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)

SIGA Technologies Business Overview & Revenue Model

Company DescriptionSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
How the Company Makes MoneySIGA Technologies generates revenue primarily through the sale of its products, notably TPOXX, which is sold to government agencies and healthcare providers for use in biodefense and public health preparedness. The company has established contracts with the U.S. government for stockpiling and procurement, which provide a significant and stable revenue stream. Additionally, SIGA may earn revenue through research and development collaborations, licensing agreements, and grants aimed at developing new antiviral therapies. Strategic partnerships with governmental and non-governmental organizations further enhance its financial stability and contribute to its earnings.

SIGA Technologies Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong product revenues, increased government funding, and a solid financial position, indicating robust performance and growth potential. However, regulatory challenges in Europe concerning tecovirimat's efficacy in treating mpox present a potential hurdle in international markets.
Q2-2025 Updates
Positive Updates
Strong Product Revenue
Product revenues for the second quarter totaled approximately $79 million, with $53 million from oral TPOXX and $26 million from IV TPOXX delivered to the U.S. Strategic National Stockpile. This fulfilled the $70 million of orders outstanding at year-end 2024.
Increased Development Funding
The company received $27 million in incremental development funding from the U.S. government, with $14 million allocated to manufacturing activities and $13 million to support the pediatric program.
Strong Financial Position
SIGA reported a pretax operating income of approximately $46 million for the quarter and maintained a cash balance of approximately $182 million with no debt as of June 30, 2025.
International Sales Success
Since 2020, SIGA has sold $135 million of oral TPOXX to 30 countries, showcasing the depth and scope of the international opportunity.
Negative Updates
Regulatory Challenges in Europe
The EMA's Committee of Medicinal Products for Human Use (CHMP) commenced a referral procedure for tecovirimat, raising questions about the product's efficacy in treating mpox and requesting additional data from recent clinical trials.
Company Guidance
During the SIGA Business Update Call for the second quarter of 2025, CEO Diem Nguyen and CFO Dan Luckshire highlighted significant progress in product revenues and development funding. SIGA achieved approximately $79 million in product revenues, including $53 million from oral TPOXX and $26 million from IV TPOXX delivered to the U.S. Strategic National Stockpile. The company also secured $27 million in additional development funding for manufacturing and pediatric programs under the BARDA 19C contract. SIGA maintained a strong financial position with a cash balance of $182 million, no debt, and a net income of $35 million for both the quarter and six months ending June 30, 2025. Fully diluted income per share stood at $0.49. The company remains focused on regulatory approvals, expanding global access, and advancing its pipeline, including a pediatric formulation and a monoclonal antibody program, while continuing to engage with the U.S. government for a new long-term agreement.

SIGA Technologies Financial Statement Overview

Summary
SIGA Technologies demonstrates strong financial health with high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. The company excels in cost control and capital management. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely.
Income Statement
85
Very Positive
SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.
Balance Sheet
88
Very Positive
The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.
Cash Flow
78
Positive
Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue179.64M138.72M139.92M110.78M133.67M124.96M
Gross Profit131.37M95.12M122.09M77.82M107.13M99.22M
EBITDA103.05M70.52M84.16M43.22M89.62M85.03M
Net Income82.18M59.21M68.07M33.90M69.45M56.34M
Balance Sheet
Total Assets235.33M244.34M254.35M195.04M214.73M149.83M
Cash, Cash Equivalents and Short-Term Investments182.46M155.40M150.15M98.79M103.14M117.89M
Total Debt570.43K546.82K564.01K528.17K466.83K449.94K
Total Liabilities26.02M28.53M57.49M24.88M40.41M20.04M
Stockholders Equity209.31M215.80M196.86M170.16M174.31M129.79M
Cash Flow
Free Cash Flow119.01M48.72M94.78M41.61M11.44M71.50M
Operating Cash Flow119.07M48.76M94.80M41.61M11.49M71.52M
Investing Cash Flow-65.16K-42.45K-21.69K0.00-50.62K-15.50K
Financing Cash Flow-43.49M-43.46M-43.42M-45.96M-26.20M-114.60M

SIGA Technologies Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price8.25
Price Trends
50DMA
7.33
Positive
100DMA
6.56
Positive
200DMA
6.05
Positive
Market Momentum
MACD
0.42
Positive
RSI
52.45
Neutral
STOCH
17.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Neutral. The current price of 8.25 is below the 20-day moving average (MA) of 8.28, above the 50-day MA of 7.33, and above the 200-day MA of 6.05, indicating a neutral trend. The MACD of 0.42 indicates Positive momentum. The RSI at 52.45 is Neutral, neither overbought nor oversold. The STOCH value of 17.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SIGA.

SIGA Technologies Risk Analysis

SIGA Technologies disclosed 40 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SIGA Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$607.93M7.3943.61%10.13%3.86%-2.60%
67
Neutral
$464.69M3.5530.24%-22.74%
54
Neutral
$611.45M928.57-2.64%-4.21%7.78%
54
Neutral
$471.80M77.48%-24.38%-94.72%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
41
Neutral
$1.23B-16.34%-1.03%8.13%
$6.07B-48.45%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SIGA
SIGA Technologies
8.25
-0.09
-1.08%
EBS
Emergent Biosolutions
8.59
-0.32
-3.59%
EVO
Evotec AG
3.49
-0.11
-3.06%
ORGO
Organogenesis Holdings
4.84
1.91
65.19%
AQST
Aquestive Therapeutics
3.85
-0.70
-15.38%
RGC
Regencell Bioscience
14.24
14.03
6680.95%

SIGA Technologies Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
SIGA Technologies Holds Annual Stockholders Meeting
Neutral
Jun 12, 2025

On June 10, 2025, SIGA Technologies held its Annual Meeting of Stockholders, where key decisions were made, including the election of eight directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the approval of an amendment to limit officer liability. The Board also amended the company’s By-laws to designate exclusive legal forums for certain claims, reflecting a strategic move to streamline legal processes and potentially reduce litigation costs.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025